UNASSIGNED: A prospective, observational cohort study recruited 97 primigravidae at 11 to 13+6 weeks gestation at GMCH. Follow-up was done at 32-34 weeks and before delivery. Development of PIH, mode of delivery, birthweight, maternal and fetal adverse outcomes were documented, analyzed and compared among three groups. In Group A-biophysical markers, Group B-biochemical markers and in Group C all variables were used.
UNASSIGNED: The mean age, maternal weight, height and BMI of patients developing gestational hypertension were 30 ± 5 years, 64.3 ± 12.5 kg, 155.8 ± 5.5 cm and 26.4 ± 4.1, respectively. Out of the 3, Group C is the best screening test for predicting the overall chance of development of gestational hypertension with a sensitivity of 97.37% and specificity of 38.98% (p < 0.0001). A mild negative correlation is seen between PlGF levels and severity of PIH (p-0.0382).
UNASSIGNED: MAP and UAD can be easily incorporated into the infrastructure of most hospitals. If the biochemical test kits are made available at a low cost through available programs such as JSSK, it can bring down the MMR by preventing gestational hypertension.
■预期,观察性队列研究在GMCH妊娠11~13+6周时招募了97只初生科。在分娩前32-34周进行随访。PIH的发展,交货方式,出生体重,母亲和胎儿的不良结局被记录,分析比较三组。在A组生物物理标记中,B组生化标志物和C组使用所有变量。
■平均年龄,产妇体重,妊娠期高血压患者的身高和BMI为30±5岁,64.3±12.5kg,分别为155.8±5.5cm和26.4±4.1cm。在3组中,C组是预测妊娠期高血压疾病发展总体机会的最佳筛查测试,其敏感性为97.37%,特异性为38.98%(p<0.0001)。在PlGF水平和PIH的严重程度之间观察到轻度负相关(p-0.0382)。
■MAP和UAD可以轻松地整合到大多数医院的基础设施中。如果通过JSSK等可用程序以低成本提供生化检测试剂盒,它可以通过预防妊娠期高血压来降低MMR。